Futura Medical Share Chat (FUM)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Futura Medical Plc	LSE:FUM	London	Ordinary Share	GB0033278473	ORD 0.2P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-1.75	-5.22%	31.75	31.00	32.50	34.50	31.75	33.50	452,393	16:27:55

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-7.2	-4.5	-	65

Futura Medical Share Discussion Threads

Showing 16926 to 16947 of 17875 messages

Chat Pages: Latest 679 678 677 676 675 674 673 672 671 670 669 668 Older

Date	Subject	Author	Discuss
03/7/2019 08:23	lets see if it can break the 40p and get to the next 50p barrier - its not a matter of if - just when :-)	ragnarr	Read Full Thread Reply
03/7/2019 06:29	What an opportunity that was. Especially when the Ceo two days ago said they have had "Huge interest." Then look at the Almost $13 billion marketplaces they are addressing,with the med and pain gels. Another judge of success to me, will be when the share price exceeds the 90p all time highs set back in 2016,therefore redeeming all long term shareholders. Given Liberum's maximum success scenario of 140p,90p is quite achievable. So hopefully everyone at least gets their money back.	j777j	Read Full Thread Reply
03/7/2019 00:31	LONDON (Alliance News) - Shares in Futura Medical PLC plunged on Friday after it said that it raised GBP5.6 million via a share placing, subscription and an open offer at a discounted price. The company placed 80 million shares at 7 pence, a 28% discount to the closing price of 9.65p on Thursday. The new shares represent 37% of the company's enlarged share capital. Shares were trading down 27% at 7.00p, on Friday. On Thursday, Futura had said it would raise GBP6 million via an accelerated bookbuild and open offer, so it missed this mark by GBP400,000. The company had said it would issue at least 71.4 million shares. Just thought I'd have a go at repeating something too as that seems to be what goes on around here. Just for those who might have forgotten, although it wasn't that long ago. :-)	glavey	Read Full Thread Reply
02/7/2019 21:46	Was looking back at previous newsflow where FUM presented at Nov 18 annual SMSNA meeting. The 2019 annual meeting is 23-27th Oct and could present an opportunity for the update. Would certainly be a great platform for this potential game changer.	k8 rhm	Read Full Thread Reply
02/7/2019 13:23	Just bought some more at .3915 but as usual showing as a sell. onwards and upwards.	duwendag	Read Full Thread Reply
02/7/2019 13:15	There is even a chance we could get results in November.June last patient recruited3.months trial so sep.One month to analyse data Oct.Gla.	j777j	Read Full Thread Reply
02/7/2019 13:12	slaccs , in the last couple of years we were in early stage of the MED program now we are just 3 or 4 months away from Phase 3 readout its now different time . Thats why Investors should never invest in early stage pharma stock ony in those who have already phase 3 programs ongoing and are close to clinical results if you like to make money.	bioking	Read Full Thread Reply
02/7/2019 12:53	I only post what I find and at the moment Liberum see 140p upside based on very conservative numbers. The $90 million upfront and milestone payments were from former house broker Singer N+1 and it is they who also forecast at 15% royalty rate. I am waiting for the share price to return to 56p as next level,which is pretty close to Liberum's 60p.	j777j	Read Full Thread Reply
02/7/2019 12:42	J777J - Any chance of some evidence behind all of your ramping or are you JB? Because nothing he has said in the last couple of years has ever come to anything. Just empty promise after empty promise. I would love for someone to prove me wrong.	slaccs	Read Full Thread Reply
02/7/2019 12:29	bg23 - at times by selling I did not want to miss a potential opportunity and at other times the value of my shares was so small it was barely worth selling. In recent weeks I've had a few small but successful spreadbets. I'm sticking at the moment. We'll both be happy if it makes 48p!	2cbg	Read Full Thread Reply
02/7/2019 11:41	A stock like FUM with close Phase 3 readout for a potential Blockbuster would be valued closer to $500 million by now in USA . Its unbelievable that FUM is still valued less than 100 million the upfront payment from a potential partner alone could be in that level .I still think buyout is more likely because its cheaper than to pay high royalties and milestones . LOVE IT	bioking	Read Full Thread Reply
02/7/2019 11:29	2cbg.......... wd, is that foresight or pig-headed stubbornness?? I need 48p and I can tell you ahead of time it is 'outright stubbornness' !! your big decision now is surely, 'cut and run' or 'believe'.......not sure where I stand on that !! although I do feel a little silly ignoring the recent research and not adding, but then again I didn't take part in the fundraising earlier this year which was a little foolish. good luck whatever you decide	bg23	Read Full Thread Reply
02/7/2019 11:12	I totally agree SOLis - JB needs to smile and learn some presentation skills. Anyway, after 3 years in FUM I finally broke even today!!	2cbg	Read Full Thread Reply
02/7/2019 10:38	Must be on the radar of biofunds across the pond.	j777j	Read Full Thread Reply
02/7/2019 10:19	large trade in the states (famdf)	mikethebike4	Read Full Thread Reply
02/7/2019 08:34	The markets that Futura's ED and topical pain gels are targeting, are in excess of $12 billion pa. If they only get a small market share with 15% royalties,the numbers are massive. On top of that the previous broker had factored in a total of $90 million in upfront and milestone payments for the med gel.	j777j	Read Full Thread Reply
02/7/2019 08:12	seen this today hxxps://www.pro activeinvestors.co.uk/companies/stocktube/13946/futura-medical-plc---elevator-pitch-13946.html	jaws6	Read Full Thread Reply
01/7/2019 12:41	The game changer is that the TPR pain gels penetrate up to 10 times faster that currently available drugs. This means not only do they work much faster but should enable the application to be cut from say 4xday to 2x day.	j777j	Read Full Thread Reply
01/7/2019 12:19	J777J 'I agree and it is actually twice the size of the ED market.' I'm not too surprised by that. Arthritis of the knee, say, not bad enough for an op, or maybe the patient too unfit for surgery, but very debilitating and painful. Lots of potentially very unpleasant side effects, some very serious, from oral NSAIDs. Try morphine or similar instead? again side effects are marked and of course they're addictive. So an effective topical NSAID such as TPR100, with reduced risk of systemic side effects, will be a valuable and welcome addition to the therapeutic armoury.	rrr	Read Full Thread Reply
01/7/2019 12:11	That was on top of $75 million paid upfront after only a phase 2 study. "Lilly agreed to pay Icos, a biotechnology start-up company that owns the rights to the drug, an up-front fee of $75 million. Analysts said that amount was extremely high for a drug that had not yet entered the final, and most important, phase of clinical trials. In another unusual arrangement, the two companies will share the marketing and sales of the drug in North America and in Europe and split the profits 50-50."	j777j	Read Full Thread Reply
01/7/2019 10:58	I agree and it is actually twice the size of the ED market. Liberum did not even include it in their last report. Topical Pain Relief Market to Reach $13.27 Bn, Globally, by 2025 Increase in geriatric population, rise in prevalence of arthritis, high demand from athletes, and lesser side effects as compared to conventional oral medicines facilitate the growth in the global topical pain relief industry. Non-opioids segment is likely to be lucrative from 2018 to 2025. Over-the-counter pain relief segment to lead in terms of revenue and growth by 2025. E-commerce segment to register the highest growth rate by 2025. Asia-Pacific to grow the fastest during the forecast period	j777j	Read Full Thread Reply
01/7/2019 10:20	Don't forget TPR100: TPR100 - Topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism Marketing authorisation application by UK commercialisation partner, Thornton & Ross (a subsidiary of STADA AG) submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in July 2018. Ongoing commercial discussions with several potential distribution partners for other territories. Any further licensing deals are expected to be after UK regulatory approval. TPR100 - Post year end Supporting Thornton & Ross on responses to initial MHRA feedback received in February 2019. hTTps://www.futuramedical.com/content/news/archive19/100419.asp	rrr	Read Full Thread Reply

Chat Pages: Latest 679 678 677 676 675 674 673 672 671 670 669 668 Older